Co-inhibition of adenosine generation and signalling: a new combination cancer therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1120887

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer is a major killer of Australians and there is a need to develop new combination therapies that halt cancer growth and spread. A metabolic product of the cancer called adenosine can be exploited by several different treatment approaches. Surprisingly we have found that both preventing adenosine generation and its effects on immune cells can together more effectively slow tumour growth and spread. If we can better understand why, this approach can be quickly brought it to clinical practice.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $587,857.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

adenosine receptors | antibody cancer therapy | metastases | mouse models | oncology

Related Links